Dose and time relationships of the radioprotector WR-2721 on locomotor activity in mice
Data up to Jan 2025
Total Citations Per Year
Abstract
References (11)
The role of WR-2721 in radiotherapy and/or chemotherapy.
1980 • 288 citations
Radiation sensitizers, their use in the clinical management of cancer
1980 • 259 citations
Biological factors affecting the radioprotective efficiency of S-2-[3-aminopropylamino]ethylphosphorothioic acid (WR-2721): LD 50(7) doses.
1971 • 98 citations
Biological Factors Affecting the Radioprotective Efficiency of S-2-[3-Aminopropylamino] Ethylphosphorothioic Acid (WR-2721). LD 50(30) Doses
1970 • 65 citations
Adverse Effects of the Radioprotector WR2721
1983 • 64 citations
Clinical trials of WR-2721 with radiation therapy
1982 • 64 citations
Behavioral Toxicity and Efficacy of WR-2721 as a Radioprotectant
1985 • 52 citations
Biodistribution of the Radioprotective Drug 35 S-Labeled 3-Amino-2-Hydroxypropyl Phosphorothioate (WR77913)
1985 • 46 citations
Effects of area postrema lesions on taste aversions produced by treatment with WR-2721 in the rat.
1986 • 11 citations
Alterations in Locomotor Activity Induced by Radioprotective Doses of 16,16-Dimethyl Prostaglandin E2
1987 • 9 citations
Deleted Work
1955 • 0 citations
Cited By (0)
No citing papers found in database